Sunnybrook's $41M Gift Aims to Make Canada a Global Hub for Clinical Trials

TORONTO, ON – April 24, 2026

Sunnybrook Health Sciences Centre is set to dramatically reshape Canada's role in global medical research, backed by a monumental $41-million philanthropic investment from the Weston family. The donation, one of the most significant of its kind in Canadian healthcare history, will overhaul the hospital's clinical trials program, aiming to accelerate the delivery of novel therapies to patients and establish the nation as a powerhouse in high-impact clinical research.

The investment directly addresses long-standing challenges within Canada's research ecosystem by funding a comprehensive expansion of infrastructure, leadership, and specialized expertise. This strategic infusion of capital is designed to streamline the complex journey from scientific discovery to patient bedside, offering new hope to patients and strengthening Canada's competitive edge on the world stage.

“Canada has the scientific strength and capability to lead clinical trials on the global stage, but too often progress is slowed by fragmented processes, inadequate infrastructure and limited capacity. The time to solve this is now,” said Dr. Andy Smith, President and CEO of Sunnybrook Health Sciences Centre, in a statement. “This generous gift accelerates a full team effort and shift across Sunnybrook to champion clinical trials as clinical care.”

Overhauling Canada's Research Engine

For years, Canada has been a recognized leader in health research, boasting a diverse population, world-class medical schools, and a publicly funded healthcare system conducive to scientific study. However, the system has been hampered by bottlenecks, including complex regulatory hurdles and a lack of integrated infrastructure, sometimes causing promising trials to move to other countries.

This $41-million investment is engineered to dismantle those barriers. The funding will establish a new, robust leadership structure at Sunnybrook, creating a dedicated Clinical Trials Chair, a Clinical Trials Methodology Chair, and an Executive Director. These roles will provide focused oversight and strategic direction for the entire program.

Furthermore, the initiative will expand the ranks of specialized teams crucial for trial execution. Experts in trial activation, implementation, precision diagnostics, biobanking, and data management will be brought on to create a more efficient, end-to-end system. A new enterprise-wide trial management system will be launched to connect teams and create a single, streamlined standard for managing the hundreds of trials underway at the institution at any given time. This foundational work is expected to significantly reduce trial start-up times and attract more international studies to Canadian soil.

From Lab Bench to Patient Bedside, Faster

The ultimate goal of this ambitious project is to directly benefit patients. By making the clinical trial process more efficient, Sunnybrook aims to shorten the timeline for promising new treatments to become available. This investment builds upon the institution's formidable track record of pioneering medical firsts.

Sunnybrook is globally recognized as a leader in focused ultrasound (FUS), a non-invasive technology that uses sound waves to treat a variety of conditions. Researchers there were the first in the world to use FUS to open the blood-brain barrier, allowing chemotherapy to reach a brain tumour in a landmark 2015 trial. This technique has since been applied to Alzheimer's disease, major depression, and obsessive-compulsive disorder in a series of first-in-North-America studies. Just recently, a Sunnybrook-led study showed this method increased survival time for glioblastoma patients by 40%.

This legacy of innovation extends far beyond focused ultrasound. The hospital's critical care group, one of the most academically productive in the world, recently led a trial that more than doubled survival rates from cardiac arrest using a novel defibrillation technique. During the COVID-19 pandemic, Sunnybrook was at the forefront, co-leading the Canadian arm of a WHO global treatment trial and coordinating a pan-Canadian study on convalescent plasma.

With over 600 clinical trials active at any given time across cancer, trauma, heart disease, high-risk pregnancy, and more, the new funding will amplify this existing expertise. The vision, as articulated by Dr. Smith, is to embed clinical trials into the fabric of everyday patient care, raising the standard for everyone.

The Power of Catalytic Philanthropy

This transformation is being powered by the Weston family, whose philanthropic arm, the Weston Family Foundation, has a long and storied history of supporting Canadian science and health innovation. This donation is a prime example of what Sunnybrook Foundation President & CEO Kelly Cole calls “catalytic philanthropy.”

“This gift goes beyond funding clinical trials to establishing and expanding the infrastructure, leadership and capacity that will ensure the most promising therapies reach patients faster, and that Canada leads that work on the global stage,” Cole stated.

This approach reflects the Weston family's established pattern of making strategic, long-term investments in areas poised for breakthrough. Their support is not just about funding individual projects but about building enduring systems that can sustain innovation. The family previously provided a $16.7 million grant in 2020 to establish the Weston Family Focused Ultrasound Initiative at Sunnybrook, an investment that helped solidify the hospital's global leadership in the field. This new, larger gift expands that vision across the entire research enterprise.

By funding the often-overlooked “scaffolding” of research—leadership, data systems, and specialized support staff—this private donation complements public funding initiatives like the Canadian Institutes of Health Research's (CIHR) Clinical Trials Fund. It provides the agility and focus needed to build a world-class operational framework that can maximize the impact of every research dollar, whether public or private.

A New Era for Canadian Medical Innovation

With this historic investment, Sunnybrook is not just expanding a program; it is championing a new philosophy where cutting-edge research and patient care are inextricably linked. The ripple effects are expected to be felt across the country. By creating a model of excellence, Sunnybrook hopes to inspire similar advancements at other Canadian institutions and attract a new generation of investigators to the field.

The enhanced capacity will make Canada a more attractive partner for global pharmaceutical companies and research consortia, bringing more trials, jobs, and investment into the country. For Canadians, it means the discoveries made in their own backyard will reach them sooner, offering new options and new hope.

As Dr. Smith noted, the ultimate outcome is that “more Canadians will access new therapies, more global trials will be led from Canada, and discoveries made here will impact care worldwide.” This $41-million investment is a powerful down payment on that future, positioning Canada to not just participate in the future of medicine, but to lead it.